Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects.

ABSTRACT: Over the past decades, our molecular understanding of acute myeloid leukemia (AML) pathogenesis dramatically increased, thanks also to the advent of next-generation sequencing (NGS) technologies. Many of these findings, however, have not yet translated into new prognostic markers or rationales for treatments. We now know that AML is a highly heterogeneous disease characterized by a very low mutational burden. Interestingly, the few mutations identified mainly reside in epigenetic regulators, which shape and define leukemic cell identity. In the light of these discoveries and given the increasing number of drugs targeting epigenetic regulators in clinical development and testing, great interest is emerging for the use of small molecules targeting leukemia epigenome. Together with their effe

SUBMITTER: Gambacorta V 

PROVIDER: S-EPMC6797914 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature